DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107 द्वारा Matthew P. Morrow, Elisabeth Gillespie, Albert Sylvester, Milan R. Amin, Peter C. Belafsky, Simon R. Best, Aaron D. Friedman, Adam M. Klein, David G. Lott, Ted Mau, Randal C. Paniello, Seth M. Pransky, Nabil F. Saba, Grace S. Tan, Sadie Wisotsky, Sarah A. Marcus, Emma L. Reuschel, Katherine S. Reed, David B. Weiner, Michael Dallas, Jeffrey M. Skolnik

पूर्ण पाठ प्राप्त करें